Rapamycin Rejuvenated 6 Aging Hearts; NewLimit Banked $435M [Best Read]
A multivitamin worth four months of aging, zero liver cancers after a microbiome reset, and rapamycin's heart rescue.
In my work as a Silicon Valley based startup executive and longevity researcher, I track the gap between what the labs are publishing and what's actually worth adding to your protocol. Here's what stood out this week — with the numbers that matter.
$435M just went into reversing aging cell by cell, human liver trial set for 2027 [STAT]
NewLimit, the cellular-reprogramming startup co-founded by Coinbase's Brian Armstrong, raised a $435 million Series C led by Founders Fund, pushing its valuation to roughly $3.1 billion. The company is trying to partially reprogram aged cells back to a younger state without erasing their identity, and plans to start its first human trial — targeting the liver — in 2027. This is the third raise in about a year, after a $130M Series B in May 2025 and $45M more in October. For longevity watchers, it's the clearest signal yet that partial reprogramming is moving from mouse studies toward the clinic, with serious capital betting on the timeline.
1mg rapamycin daily for 8 weeks improved heart filling in all six men aged 70–76 [GeroScience]
In a GeroScience pilot study, six healthy men aged 70–76 took 1 mg of rapamycin daily for eight weeks, and cardiac MRI showed statistically significant improvements in diastolic function — transmitral blood flow, peak filling rate, and blood acceleration all rose in every participant, alongside better endothelial function. Diastolic decline, a stiffer heart that fills poorly, is one of the most reliable signatures of cardiac aging, so reversing it even modestly is notable. The sample is tiny and uncontrolled, so treat it as a signal, not a protocol — but it's a clean, quantified human result for the most-studied molecule in geroscience.
A daily multivitamin bought back about four months of biological aging over two years [Nature Medicine]
Researchers at Mass General Brigham analyzed 958 healthy older adults (average age 70) from the COSMOS randomized trial and found that two years of a daily multivitamin slowed biological aging across all five DNA-methylation clocks they measured, with two mortality-linked clocks reaching statistical significance. The overall effect equaled roughly four fewer months of biological aging over the two-year window, and the benefit was largest in people already aging faster than their chronological age at baseline. It's a modest but cheap, accessible intervention with hard epigenetic data behind it — a reminder that the basics still move the needle.
Resetting old mice to their own youthful microbiome cut liver cancer to zero of eight [Digestive Disease Week]
In work presented at Digestive Disease Week 2026, scientists at UT Medical Branch banked fecal samples from young mice, then transplanted each animal's own younger microbiome back as it aged. None of the eight treated mice developed liver cancer, versus two of eight untreated controls, and the treated group showed less inflammation, less DNA damage, and suppressed MDM2 — a cancer-linked gene that runs high in aged livers. The team reports the reset reversed several aging hallmarks at once, including fibrosis, mitochondrial decline, and telomere attrition. It's still mouse data, but it reframes the aging microbiome as an active driver of decline rather than a passive marker.
Shingles-vaccinated adults over 70 aged slower on epigenetic clocks, and it held 4+ years [USC Leonard Davis]
A USC analysis of more than 3,800 Americans aged 70 and older in the Health and Retirement Study found that those who received the shingles vaccine showed slower biological aging across seven markers, including epigenetic and transcriptomic clocks, after adjusting for health and demographics. The effect appeared durable: people vaccinated four or more years before their blood draw still aged more slowly than the unvaccinated. The likely mechanism is reduced "inflammaging" — by preventing viral reactivation, the vaccine may quiet the chronic low-grade inflammation tied to heart disease, frailty, and cognitive decline. A reminder that immune maintenance is longevity infrastructure, not just infection defense.
A naked mole rat gene gave mice 4.4% longer median life and stronger tumor resistance [University of Rochester]
University of Rochester researchers engineered mice to carry the naked mole rat version of the hyaluronan synthase 2 gene, which drives production of high-molecular-weight hyaluronic acid (HMW-HA). Naked mole rats carry about ten times more HMW-HA than mice or humans and can live up to 41 years — nearly ten times longer than similar-sized rodents — while rarely developing cancer. The modified mice resisted spontaneous and chemically induced tumors, had less age-related inflammation and better gut health, and lived about 4.4% longer at the median. The team is now testing molecules that slow HMW-HA breakdown, aiming to translate the mechanism to humans.